Understanding how different brain cells are affected by tau protein in Alzheimer's disease
Cell-Type Specific Vulnerability to Tauopathy and Its Prevention in Multiple Models
This study is looking at how certain brain cells are affected by a harmful protein linked to Alzheimer's disease, using fruit flies, mice, and human cells, to find ways to help clear this protein and protect brain health for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11046673 on NIH RePORTER |
What this research studies
This research investigates how specific types of brain cells are vulnerable to tau protein accumulation, which is a key factor in Alzheimer's disease. The study uses models from fruit flies and mice, as well as human cells, to explore how these cells respond to tau toxicity and how new antibodies can help clear tau from the brain. By identifying which cells are most affected, the research aims to develop targeted therapies that could prevent cell death and improve brain health in Alzheimer's patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or other tauopathies.
Not a fit: Patients with tauopathies not involving tau protein accumulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of Alzheimer's disease by enhancing the clearance of toxic tau proteins.
How similar studies have performed: Previous research has shown promise in targeting tau pathology with antibodies, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Sigurdsson, Einar M — New York University School of Medicine
- Study coordinator: Sigurdsson, Einar M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.